Grantee Research Project Results
Selected Publications Details for Grant Number R826886C002
Genetic Susceptibility to Pesticides (Paraoxonase Polymorphism or PON1 Study)
RFA:
Centers for Children's Environmental Health and Disease Prevention Research (1998)
Other Views
- All
Publications - Selected
Publication Types - Journal
Articles - Publications Submitted
After Final Report - Redisplay this page without
Reference Title, Journal, and Author Columns - Display this Page
in RIS Format
Reference Type | Reference Title | Journal | Author | Citation | Progress Report Year | Document Sources |
---|---|---|---|---|---|---|
Book Chapter | PON1 polymorphisms. | None | Brophy VH, Jarvik GP, Furlong CE | Brophy VH, Jarvik GP, Furlong CE. PON1 polymorphisms. In: Costa LG, Furlong CE, eds. Paraoxonase (PON1) in Health and Disease: Basic and Clinical Aspects. Boston, MA: Springer, 2002, Chapter 3, pp. 53-77. |
R826886 (2000) R826886C002 (2001) R826886C002 (2002) R831709 (2007) |
|
Book Chapter | PON1 and organophosphate toxicity. Chapter 8. | None | Costa LG, Li W-F, Richter RJ, Shih DM, Lusis AJ, Furlong CE | Costa LG, Li W-F, Richter RJ, Shih DM, Lusis AJ, Furlong CE. PON1 and organophosphate toxicity. Chapter 8. In: Costa LG, Furlong CE, eds. Paraoxonase (PON1) in Health and Disease: Basic and Clinical Aspects. Boston, MA: Kluwer Academic Publishers, 2002. |
R826886C002 (2001) R826886C002 (2002) |
|
Book Chapter | Perspectives in PON1 research. | None | Costa LG, Furlong CE | Costa LG, Furlong CE. Perspectives in PON1 research. In: Costa LG, Furlong CE, eds. Paraoxonase (PON1) in Health and Disease: Basic and Clinical Aspects. Boston, MA: Springer, 2002, Chapter 10, pp. 197-210. |
R826886 (2000) R826886C002 (2002) |
|
Journal Article | Polymorphisms in the human paraoxonase (PON1) promoter. | PHARMACOGENETICS | Brophy VH, Hastings MD, Clendenning JB, Richter RJ, Jarvik GP, Furlong CE | Brophy VH, Hastings MD, Clendenning JB, Richter RJ, Jarvik GP, Furlong CE. Polymorphisms in the human paraoxonase (PON1) promoter. Pharmacogenetics 2001;11(1):77-84. |
R826886 (2000) R826886C002 (2001) |
|
Journal Article | Effects of 5' regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. | AMERICAN JOURNAL OF HUMAN GENETICS | Brophy VH, Jampsa RL, Clendenning JB, McKinstry LA, Jarvik GP, Furlong CE | Brophy VH, Jampsa RL, Clendenning JB, McKinstry LA, Jarvik GP, Furlong CE. Effects of 5' regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. American Journal of Human Genetics 2001;68(6):1428-1436. |
R826886 (2000) R826886C002 (2001) R831709 (2007) |
|
Journal Article | The role of paraoxonase (PON1) in the detoxication of organophosphates and its human polymorphism. | CHEMICO-BIOLOGICAL INTERACTIONS | Costa LG, Li WF, Richter RJ, Shih DM, Lusis A, Furlong CE | Costa LG, Li WF, Richter RJ, Shih DM, Lusis A, Furlong CE. The role of paraoxonase (PON1) in the detoxication of organophosphates and its human polymorphism. Chemico–Biological Interactions 1999;119-120:429-438. |
R826886 (2000) R826886C002 (2000) |
|
Journal Article | The emerging field of ecogenetics. | NEUROTOXICOLOGY | Costa LG | Costa LG. The emerging field of ecogenetics. Neurotoxicology 2000;21(1-2):85-89. |
R826886 (2000) R826886C002 (2000) |
|
Journal Article | Paraoxonase (PON1) as a biomarker of susceptibility for organophosphate toxicity. | BIOMARKERS | Costa LG, Richter RJ, Li W-F, Cole T, Guizzetti M, Furlong CE | Costa LG, Richter RJ, Li W-F, Cole T, Guizzetti M, Furlong CE. Paraoxonase (PON1) as a biomarker of susceptibility for organophosphate toxicity. Biomarkers 2003;8(1):1-12. |
R826886 (2000) R826886C002 (2002) R831709 (2005) R831709 (2007) R831709C002 (2004) |
|
Journal Article | Functional genomics of the paraoxonase (PON1) polymorphisms: effects on pesticide sensitivity, cardiovascular disease, and drug metabolism. | ANNUAL REVIEW OF MEDICINE | Costa LG, Cole TB, Jarvik GP, Furlong CE | Costa LG, Cole TB, Jarvik GP, Furlong CE. Functional genomics of the paraoxonase (PON1) polymorphisms: effects on pesticide sensitivity, cardiovascular disease, and drug metabolism. Annual Review of Medicine 2003;54:371-392. |
R826886 (2000) R826886C002 (2002) R831709 (2005) R831709 (2007) R831709C002 (2004) |
|
Journal Article | The PON1 gene and detoxication. | NEUROTOXICOLOGY | Furlong CE, Li WF, Brophy VH, Jarvik GP, Richter RJ, Shih DM, Lusis AJ, Costa LG | Furlong CE, Li WF, Brophy VH, Jarvik GP, Richter RJ, Shih DM, Lusis AJ, Costa LG. The PON1 gene and detoxication. NeuroToxicology 2000;21(4):581-587. |
R826886 (2000) R826886C002 (2001) |
|
Journal Article | Genetic and temporal determinants of pesticide sensitivity: role of paraoxonase (PON1). | NEUROTOXICOLOGY | Furlong CE, Li WF, Richter RJ, Shih DM, Lusis AJ, Alleva E, Costa LG | Furlong CE, Li WF, Richter RJ, Shih DM, Lusis AJ, Alleva E, Costa LG. Genetic and temporal determinants of pesticide sensitivity: role of paraoxonase (PON1). NeuroToxicology 2000;21(1-2):91-100. |
R826886 (2000) R826886C002 (2000) R826886C002 (2001) |
|
Journal Article | Pharmacogenomic considerations of the paraoxonase polymorphisms. | PHARMACOGENETICS | Furlong CE, Cole TB, Jarvik GP, Costa LG | Furlong CE, Cole TB, Jarvik GP, Costa LG. Pharmacogenomic considerations of the paraoxonase polymorphisms. Pharmacogenomics 2002;3(3):341-348. |
R826886 (2000) R826886C002 (2002) |
|
Journal Article | Genetic factors in susceptibility: serum PON1 variation between individuals and species. | HUMAN AND ECOLOGICAL RISK ASSESSMENT | Furlong CE, Li W-F, Shih DM, Lusis AJ, Richter RJ, Costa LG | Furlong CE, Li W-F, Shih DM, Lusis AJ, Richter RJ, Costa LG. Genetic factors in susceptibility: serum PON1 variation between individuals and species. Human and Ecological Risk Assessment 2002;8(1):31-43. |
R826886 (2000) R826886C002 (2002) |
|
Journal Article | Catalytic efficiency determines the in-vivo efficacy of PON1 for detoxifying organophosphorus compounds. | PHARMACOGENETICS | Li WF, Costa LG, Richter RJ, Hagen T, Shih DM, Tward A, Lusis AJ, Furlong CE | Li WF, Costa LG, Richter RJ, Hagen T, Shih DM, Tward A, Lusis AJ, Furlong CE. Catalytic efficiency determines the in-vivo efficacy of PON1 for detoxifying organophosphorus compounds. Pharmacogenetics 2000;10(9):767-779. |
R826886 (2000) R826886C002 (2000) R826886C002 (2001) |
|
The perspectives, information and conclusions conveyed in research project abstracts, progress reports, final reports, journal abstracts and journal publications convey the viewpoints of the principal investigator and may not represent the views and policies of ORD and EPA. Conclusions drawn by the principal investigators have not been reviewed by the Agency.